FDA approval of a psychedelic medicine should not leave the active ingredient trapped in Schedule I.
The Coalition for Psychedelic Rescheduling is working to prevent dual scheduling: a system where one approved branded drug becomes lawful while the same active pharmaceutical ingredient remains Schedule I for research, manufacturing, compounding, and future treatment innovation.
The public assumption is simple: FDA approves a psychedelic medicine, DEA moves the substance out of Schedule I, and doctors can treat patients. The coalition’s premise is that the law can produce a very different result.
DEA can schedule an approved finished drug product differently from the bulk active pharmaceutical ingredient used to make medicine, run new studies, test different doses, or develop new formulations. That creates two regulatory worlds for the same active molecule.
The coalition’s comparison uses ketamine as the Schedule III model and a hypothetical split scheduled psilocybin product as the contrast.
Leaving the API in Schedule I preserves a separate registration, protocol, security, quota, and supply burden for future studies involving the molecule.
New strengths, formulations, routes of administration, and treatment protocols can continue to depend on access to a Schedule I ingredient.
If only the approved finished drug leaves Schedule I, the legal supply pathway can remain centered on a single branded formulation rather than the active ingredient.
The coalition’s position is that moving the pharmaceutical ingredient with an approved medicine can support regulated research and dosing rather than leaving the underlying molecule in the illicit market.
When FDA approves a product containing psilocybin, MDMA, LSD, or another psychedelic active ingredient, the coalition wants federal scheduling policy to address the bulk active pharmaceutical ingredient as well as the branded finished drug.
This is not a call to legalize street use. It is a call to create a lawful pharmaceutical and research pathway for the active ingredient when the federal government recognizes an approved medical use.
The coalition brings legal, scientific, patient, veteran, research, policy, and industry voices together around a precise federal outcome.
Ground the policy case in evidence and the statutory framework governing scheduling.
Focus attention on the federal evaluation of medical use, abuse potential, and the relevant scheduling factors.
Make the distinction between rescheduling a finished product and rescheduling the underlying API visible before the final scheduling architecture is set.
Seek a federal outcome that does not leave the bulk active ingredient in Schedule I while recognizing medical use in an approved product.
The coalition should be broader than any one company or product. The policy affects the future of psychedelic research, treatment development, patient access, and competition.
Founding member logos and organizational endorsements should appear here only after written approval.
Shane Pennington brings direct experience with the federal agencies, statutes, courts, and rescheduling proceedings at the center of this coalition’s mission.
A lawyer who has already worked inside the exact federal machinery this coalition is trying to change.
Shane’s value to the coalition is not simply subject matter expertise. His record connects the core pieces of the strategy: psychedelic rescheduling, DEA decision making, Schedule I research access, federal appellate litigation, and coalition based scheduling reform.
Draft public positioning. Shane’s coalition title, biography, headshot, Blank Rome affiliation treatment, quotes, and any firm branding require Shane and Blank Rome approval before publication.
The first company to secure FDA approval should be rewarded for bringing a medicine to market. The coalition’s position is that approval should not create a permanent regulatory moat around the underlying molecule.
If the federal government recognizes an accepted medical use for an active ingredient in an approved medicine, the scheduling framework should allow responsible research, lawful pharmaceutical development, and future clinical innovation around that ingredient under appropriate controls.
Researchers, clinicians, veterans organizations, patient advocates, policy organizations, legal experts, and responsible industry participants can help build the federal case for rescheduling the active ingredient with the approved medicine.
Replace placeholder email addresses before launch.